AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03062020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QUIPP
Description: Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
Study NCT00750724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg sodium hyaluronate GO ON
Description: 25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks
Study NCT00750724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline,2 ml., intraarticular weekly for 5 weeks
Study NCT02179411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tilt test
Study NCT03028753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder scan post void residual
Description: After voiding on the commode, all subjects will have a post void residual measured by bladder scanner
Study NCT03028753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Straight catheter post void residual
Description: After voiding on the commode and having a post void residual measured by bladder scanner, all subjects will have a post void residual measured by straight catheter performed with usual sterile technique.
Study NCT02996630 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sonography
Description: Fetal Ultrasound exploration
Study NCT03028753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Back fill voiding trial
Description: Prior to catheter removal, all subjects will undergo a back fill voiding trial. The bag of the foley catheter will be removed and the subjects bladder will be filled with 300cc of normal saline (or as much as they can tolerate). The foley catheter will then be removed and the subject will be asked to void on the commode. The voided volume will be measured.
Study NCT00298259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative fixation of fractured ribs
Description: ORIFof fractured ribs in flail chest patients
Study NCT03412747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.
Study NCT03412747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.
Study NCT02996630 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Fetal MRI for brain study
Study NCT02996630 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bailey Test
Description: Neurodevelopment paediatric assessment test performed at 2 years of age.
Study NCT03412747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab will be administered according to the labeling recommendations.
Study NCT03412747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
Study NCT03412747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
Study NCT05343520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises
Description: Pelvic floor muscle exercises were applied to the pregnant women in the experimental group from the 30th gestational week to the 6th postpartum week.
Study NCT00776217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg orally disintegrating tablets
Study NCT02996630 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical intervention
Description: Congenital Heart Disease repair
Study NCT02996630 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain monitoring
Description: EEG and continuous brain oximetry before surgery.
Study NCT02996630 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cord blood sample
Description: Cord blood samples will be taken after birth in both groups.
Study NCT06522789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal cross-linking procedure
Description: Standard Dresden protocol corneal cross-linking procedure The CXL procedure adhered to the standard Dresden protocol. All patients received topical anaesthetic (Tetracaine HCL 0.5%, Alcon Forth Worth, Texas) and a miotic (Isopto Carpine 2% HCl, Alcon, Fort Worth, Texas) drops 30 minutes before the procedure. The periocular region and conjunctival sac were washed with 10% povidone-iodine (Betadine 10%, Alcaloid, Skopje). Manual epithelial scraping with a crescent knife followed. Pachymetry was kept over 400 μm during the procedure and measured with an ultrasound hand pachymeter (Pocket II, Quantel Medical, Cournon d'Auvergne, France). Riboflavin (Peschke D, Peschke Trade, Huenenberg, Switzerland) was applied every 3 minutes for 30 minutes. We performed corneal UV-A radiation with a wavelength of 370 nm and energy of 3mW using a UVA CXL lamp (VEGA CBM-X-Linker, Carleton Optical, Chesham, UK) for 30 minutes (6 cycles of 5 minutes each).
Study NCT02498288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin: Reference Medication 1
Description: Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
Study NCT02498288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin: Reference Medication 2
Description: Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
Study NCT02498288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin: Test Medication
Description: Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
Study NCT01735448 — intervention group
Intervention type: OTHER
Intervention: Focus group
Description: Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.~The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.~We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research.
Study NCT00776217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loratadine 10 mg orally disintegrating tablets
Study NCT00558038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: AST-120
Study NCT00558038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactulose
Description: lactulose
Study NCT02720302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOFT
Description: SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
Study NCT02720302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeleSOFT
Description: The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
Study NCT01405833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00010 (Neublastin)
Description: Multiple doses, weight-based IV administration
Study NCT01405833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose IV matched placebo
Study NCT04473898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Aerobic exercises using all body muscles and that one can do on their own after being shown online
Study NCT04473898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patient education about covid-19 and hygiene education
Study NCT04473898 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Patient Education
Description: Patient education about covid-19 and hygiene education
Study NCT01735448 — intervention group
Intervention type: OTHER
Intervention: One-on-one interviews
Description: One-on- one interviews will be held with both medical clinicians and key stakeholders and will be conducted by existing TQEH (The Queen Elizabeth Hospital), Clinical Practice Unit employees, experienced in qualitative research. Informed consent will be required and the interview will be audio taped to allow analysis of the qualitative data. All interviews will remain anonymous, unless the interviewee prefers to be named. In this case, they will be named in the acknowledgement section of all publications and presentations. Moderator guides have been developed and reviewed in the same process undergone by the focus group moderator guides
Study NCT01735448 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: A four page survey will be administered to all focus group and interview participants in addition to select cohorts including tobacco related special interest groups of the Thoracic Society of Australia and New Zealand (TSANZ). The survey will include demographic data, smoking history and current smoking status (questions related to smoking for current tobacco users include the Fagerstrom test for nicotine dependence, multiple Likert scales for cravings, motivation to quit, confidence etc.) and Likert scales examining perceptions, attitudes and knowledge about tobacco use, cessation, prevention, health and research in the Aboriginal setting.
Study NCT04473898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Exercise Training
Description: Respiratory exercises that one can do on their own after being shown online
Study NCT02825173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-G
Description: Intervention:~Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques
Study NCT03097484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lavender and chamomile essential oils
Description: Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
Study NCT01247285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride
Description: 90 mg Capsules
Study NCT01247285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROZAC WEEKLY®
Description: 90 mg Capsules
Study NCT02786550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Description: A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
Study NCT02786550 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: The same amount (3 cc) of Normal saline will be injected to the lateral part of obicularis oculis muscle
Study NCT00629733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO-14
Study NCT00461513 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intervention
Description: Disease management has emerged as a promising strategy to improve the outcomes of patients with CHF. Disease management in this study will use a multidisciplinary collaborative care, leveraging health information technology, and focusing on patient self-care.Collaborative care is the use of multidisciplinary teams to deliver evidence-based treatment to a defined population of patients with chronic illness.
Study NCT02686684 — intervention group
Intervention type: DRUG
Intervention: Dimethyl fumarate
Study NCT02109640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targinact
Description: Post-operative analgesia
Study NCT02109640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Postoperative analgesia
Study NCT00141219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 150-600mg/day, BID
Study NCT00141219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01009151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Self Care Tracker
Description: Web-based home tele-monitoring system serving congestive heart failure patients at the University of Michigan Health System. The intervention consists of daily reporting via the Internet on parameters specified in clinical protocols, including weight, blood pressure, heart rate and heart failure symptoms. These protocols contain automated trigger mechanisms when certain values are exceeded to alert the provider and the patient for the need to take appropriate remedial action. The system provides links to educational material on heart failure and reminders for self-care measures.
Study NCT01009151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Care Self Tracker
Description: Web-based Home Tele-monitoring System
Study NCT02280369 — intervention group
Intervention type: DEVICE
Intervention: Automated abdominal binder
Description: Inflatable abdominal binder
Study NCT04108052 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Low CT scanner without injection dose
Description: CT scan acquisition will be performed at 140 kVp (kilovolt peak), 10 mAs(milliampere), CTDI 1.3 mGy with an irradiation dose 0.51 mSv (milliSievert). The CT image will be reconstructed and analyzed in parenchyma window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
Study NCT02109640 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic segmental colectomy
Study NCT02109640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic segmental colectomy
Study NCT04108052 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Ultra-low dose CT scanner without injection
Description: CT acquisition will be performed at 80 kVp for patient with a body mass index\<30, and 100 kVp with a body mass index>30, 10 mAs, CTDI 0.3 and 0.6 mGy with an irradiation dose 0.15-0.30 mSv. The CT images will be reconstructed and analyzed in mediastinal window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
Study NCT04458129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with polyethylene glycol (Macrogol 4000)
Description: 3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets. Dosage of 0.7 g/kg/day, with a maximum dose of 20 g/day.
Study NCT02646007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MSC transplantation
Description: Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
Study NCT03155126 — intervention group
Intervention type: OTHER
Intervention: Fluid resuscitation
Description: Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium
Study NCT03820882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catfish
Description: Patients will be treated for mechanical recanalization with Catfish within 8 hours after stroke onset plus standard medical management.
Study NCT03820882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire FR
Description: Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
Study NCT03145311 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Study NCT03145311 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Study NCT01366326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide
Description: Subcutaneous MNTX
Study NCT00626275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859
Study NCT00626275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Study NCT00626275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04001543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunomodulating oral supplementation
Description: Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
Study NCT04001543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sip feed control
Description: Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
Study NCT02360826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Study NCT02192125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REWIRE-System
Description: The REWIRE rehabilitation platform consists of three hierarchical components:~1. patient station (PS), which is installed in the home environment of the patient:~   Includes:~   Laptop with software - Game Tymoplate® - balanceboard Kinect® - 3D tracking~2. Hospital Station (HS), which allows an exchange of information with more patient station and is served by the therapists in the hospital;~   Includes:~   Laptop MySQL- database~3. station networking (NS), which allows a combination of a several of HS. database
Study NCT02360826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study NCT04283071 — intervention group
Intervention type: DEVICE
Intervention: Boxed infrared gross kinematic assessment tool
Description: An optical motion capture system, which records the movements of infrared emitting diodes (IREDs) in three-dimensional (3D) space by triangulating images from a pair of infrared cameras
Study NCT00726648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 50mg capsules, 100mg bid for 4 weeks
Study NCT00726648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 250mg capsules, 500mg bid for 4 weeks
Study NCT00726648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 250mg capsules, 1000mg bid for 4 weeks
Study NCT00726648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP323
Description: 250mg capsules, 1000mg daily for 4 weeks
Study NCT00726648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsules for 4 weeks
Study NCT00726648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules for 4 weeks
Study NCT02544568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals
Description: At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
Study NCT03596866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib Tablets.
Study NCT03596866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alectinib
Description: Alectinib Capsules.
Study NCT05774834 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01544426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy and endometrial snip
Description: Office hysteroscopy with endometrial snip
Study NCT01544426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Office hysteroscopy
Description: Office hysteroscopy
Study NCT02489071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training Program
Study NCT02489071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Program
Study NCT00744926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc, once weekly
Study NCT00744926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc, once weekly
Study NCT00744926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
Study NCT01434173 — intervention group
Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days